Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia

Ernesto Diaz-Flores, PhD, Evan Q. Comeaux, PhD, Kailyn Kim, Kyle Beckman, BS, Kara L. Davis, DO, Kevin Wu, Jon Akutagawa, Linda Holmfeldt, PhD, Benjamin S. Braun, MD PhD, Charles Mullighan, MBBS, MSc, MD, Mignon L. Loh, MD

Blood (2016) 128 (22): 280.

https://doi.org/10.1182/blood.V128.22.280.280

Published: 2016

Journal Articles

Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia

Rebecca S. LaRue, PhD, Hanh Nguyen, Karen Sachs, Nurul Azyan Mohd Hassan, Ernesto Diaz-Flores, PhD, Susan K. Rathe, Aaron G. Sarver, Ph.D., Sean C. Bendall, Ngoc A. Ha, Miechaleen D. Diers, B.S., Garry P. Nolan, PhD, Kevin Shannon, MD, Zohar Sachs, MD, PhD, David A. Largaespada, PhD

Blood (2013) 122 (21): 819.

https://doi.org/10.1182/blood.V122.21.819.819

Published: 2013

Journal Articles

Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9 -Specified Gene Expression Signature

Zohar Sachs, MD, PhD, Hanh Nguyen, Nurul Azyan Mohd Hassan, Susan K Rathe, Karen Sachs, Ph. D., Ernesto Diaz-Flores, PhD, Sean C Bendall, PhD, Miechaleen D Diers, Garry P. Nolan, Ph. D., Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2012) 120 (21): 5116.

https://doi.org/10.1182/blood.V120.21.5116.5116

Published: 2012

Journal Articles

Mechanisms of Relapse Following Targeted Therapy in An NRAS G12V and Mll-AF9 Driven Mouse Model of AML

Craig E. Eckfeldt, MD, PhD, Ernesto Diaz-Flores, PhD, Michaeleen D. Diers, Susan K. Rathe, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2011) 118 (21): 2620.

https://doi.org/10.1182/blood.V118.21.2620.2620

Published: 2011

Journal Articles

Delineating Critical Effectors of Remission Induction in a Mouse Model of AML

Zohar Sachs, MD, PhD, Susan K. Rathe, Ernesto Diaz-Flores, PhD, Miechaleen D Diers, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2011) 118 (21): 5232.

https://doi.org/10.1182/blood.V118.21.5232.5232

Published: 2011

Journal Articles

Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia

Hongtao Liu, MD, PhD, Ernesto Diaz-Flores, PhD, Xavier Poiré, MD, Olatoyosi Odenike, MD, Greg Koval, MS, Greg Malnassy, MS, Pamela Ihonor, MS, Yanming Zhang, MD, Michelle M. Le Beau, PhD, Kevin Shannon, MD, Wendy Stock, MD

Blood (2010) 116 (21): 3978.

https://doi.org/10.1182/blood.V116.21.3978.3978

Published: 2010

Journal Articles

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Zohar Sachs, MD, PhD, Ernesto Diaz-Flores, PhD, Miechaleen D Diers, Karen Sachs, Sean C Bendall, PhD, Harris G Fienberg, Susan K Rathe, Garry P. Nolan, Ph.D., Kevin Shannon, MD, David Largaespada, PhD

Blood (2010) 116 (21): 3160.

https://doi.org/10.1182/blood.V116.21.3160.3160

Published: 2010

Journal Articles

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

Xavier Poiré, MD, Ernesto Diaz-Flores, PhD, Rachel Joy Bergerson, Dorie Sher, B.S., Olatoyosi Odenike, MD, Kevin Shannon, MD, David Largaespada, PhD, Wendy Stock, MD

Blood (2009) 114 (22): 1032.

https://doi.org/10.1182/blood.V114.22.1032.1032

Published: 2009

Journal Articles

PI3 Kinase, Phospholipase C (PLC)-γ, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.

Ernesto Diaz-Flores, PhD, Hana Leah Goldschmidt, BA, Philippe Depeille, Ph.D, Victor Ng, BA, Jeroen Roose, Assistant, Professor, Kevan Shokat, Ph.D., Benjamin S. Braun, MD, PhD, Kevin Shannon, MD

Blood (2009) 114 (22): 2512.

https://doi.org/10.1182/blood.V114.22.2512.2512

Published: 2009

Journal Articles

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.

Ernesto Diaz-Flores, PhD, Margaret VanMeter, BS, Jennifer O. Lauchle, M.D., Benjamin S. Braun, M.D.-Ph.D, Kevin M. Shannon, M.D.

Blood (2007) 110 (11): 2196.

https://doi.org/10.1182/blood.V110.11.2196.2196

Published: 2007

Journal Articles

A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.

Nikesh Kotecha, Nikki J. Flores, Jonathan M. Irish, PhD, Debbie Sakaguchi, MD, Sophie Archambeault, Ernesto Diaz-Flores, PhD, Marc Coram, PhD, Kevin M. Shannon, MD, Garry P. Nolan, PhD, Mignon L. Loh, MD

Blood (2007) 110 (11): 546.

https://doi.org/10.1182/blood.V110.11.546.546

Published: 2007

Journal Articles

Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow.

Margaret E.M. Van Meter, BA, Ernesto Diaz-Flores, PhD, Joehleen A. Archard, BS, Nikesh Kotecha, BS, Amit J. Sabnis, BS, Jonathan M. Irish, PhD, Garry P. Nolan, PhD, Kevin M. Shannon, MD, Benjamin S. Braun, MD, PhD

Blood (2005) 106 (11): 239.

https://doi.org/10.1182/blood.V106.11.239.239

Published: 2005

NARROW

BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia

Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia

Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9 -Specified Gene Expression Signature

Mechanisms of Relapse Following Targeted Therapy in An NRAS G12V and Mll-AF9 Driven Mouse Model of AML

Delineating Critical Effectors of Remission Induction in a Mouse Model of AML

Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

PI3 Kinase, Phospholipase C (PLC)-γ, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.

A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.

Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only